Synapse - Global Drug Intelligence Database

WCLC 2026 Plenary Studies Clinical Evidence Review Report

This report frames the IASLC World Conference on Lung Cancer (WCLC 2026), held 12–15 September 2026 in Seoul, Republic of Korea, around four plenary themes (PL01–PL04) and a dedicated artificial-intelligence-in-oncology track. It provides an integrated clinical-evidence review of nine plenary-anchored studies spanning screening, access and survivorship; small cell lung cancer (SCLC) post-induction strategy and relapsed-SCLC antibody–drug conjugates (ADCs); first-line PD-L1-high and EGFR-driven non-small cell lung cancer (NSCLC); and a mixed EGFR exon 20 insertion / ROS1 / HER2 group. The report is organized around evidence maturity, so each study's clinical question, design, population, treatment versus comparator, endpoints, disclosed findings, and unresolved questions are assessed on the same footing. It clearly separates established readouts (ADAURA's long-term follow-up, PAPILLON's PFS benefit with a pending OS analysis) from interim or topline-only disclosures (REZILIENT3, DESTINY-Lung04), and treats the negative EVOKE-03/KEYNOTE-D46 result — and its subsequent programme discontinuation by Merck and Gilead — as an important interpretive anchor rather than a footnote. It also carefully distinguishes commonly conflated assets and definitions, including Tam-Peli/YL201 as a B7-H3 ADC (not a TROP2 ADC and not risvutatug rezetecan) and ARROS-1's “TKI-naive” cohort of zidesamtinib-treated ROS1-positive patients (not necessarily treatment-naive overall). Aimed at thoracic oncologists, clinical researchers, and medical affairs and market-access teams, the report offers a decision-oriented reference that helps readers rapidly locate where genuinely new information is expected at WCLC 2026, where already-known interim signals are maturing, and where cautious interpretation and independent verification remain essential.

Read →

ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings

This report distills the late-breaking and hot-line evidence from the European Society of Cardiology Congress held in Munich, 28–31 August 2026. It provides a side-by-side analysis of seven pivotal trials — CARDIO-TTRansform, ACACIA-HCM, LIBREXIA-ACS, SINGLE-AF, STAREE, PRESC1SE-MI, and CMR GUIDE — spanning ATTR cardiomyopathy, nonobstructive HCM, post-ACS antithrombotic therapy, atrial fibrillation stroke prevention, primary prevention in older adults, ED triage of suspected MI, and ICD-based primary prevention in intermediate-LVEF populations. Built around the underlying numbers, the report presents every trial's sample size, intervention, follow-up, primary endpoint effect estimate (HR/RR/OR with 95% CI and P value), and serious adverse-event profile. A benefit–risk classification grid, safety-signal visualizations, and five interpretive caveats — including the aficamten LVEF-reduction signal, the hypothesis-generating nature of the CARDIO-TTRansform subgroup finding, and the divergence between STAREE's two co-primary endpoints — help readers gauge evidence strength without being misled by isolated P values. Aimed at cardiologists, clinical researchers, and medical affairs and market-access teams, the report closes by clearly separating findings that are clinically actionable now (ACACIA-HCM, SINGLE-AF, STAREE cardiovascular endpoint, PRESC1SE-MI safety) from those that remain hypothesis-generating or non-confirmatory (CARDIO-TTRansform subgroup, LIBREXIA-ACS, CMR GUIDE). A high-density, decision-oriented reference to the strongest cardiovascular evidence out of ESC 2026.

Read →

Oligonucleotide Therapeutics Report: What Patent Intelligence Reveals About the Next Wave of Platform Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Patent Intelligence: who owns the freedom to operate, and where the platform race is headed next. Oligonucleotide therapeutics are entering a new phase of platform competition, not decided by who owns a therapeutic sequence but by who controls the technology around it. As the field moves beyond early rare-disease proof points into common indications with larger end markets, the centre of value is shifting toward the broader stack: chemical modification, conjugation, delivery, manufacturing, target-tissue access, and platform scalability. This shift raises the bar for Intellectual Property (IP) intelligence. Keyword-based patent search is no longer enough because the signal that matters has moved away from the sequence and into the technology around it (chemical modifications, delivery and conjugation disclosures, and process claims), and increasingly into who is emerging as a platform owner. Reading the landscape now means connecting patent, biological, chemical, clinical, and commercial intelligence in one view. This report uses Patsnap Analytics, Bio, and Synapse to examine how oligonucleotide IP is evolving across four strategic questions: • Who owns the core patent estate across approved products, clinical candidates, and enabling platforms? • How are companies protecting platform value through sequence, formulation, new-use, delivery, conjugation, process, and lifecycle claims? • Where is innovation concentrating across chemistry, delivery, manufacturing, geography, and data assets? • What does the 2027–2036 expiry wave unlock for incumbents, fast-followers, and new platform entrants?

Read →